To check the pulse on the U.S. biopharma industry, few states are better situated than the life sciences hotspot that is ...

Phreesia is bringing Sesame Street to the doctor’s office. The patient activation company has partnered with the nonprofit ...

With the nod, Zemcelpro offers a first-of-its-kind option to many of the thousands of patients who are diagnosed each year in ...

As for why ClevelandDx has chosen to re-up the “PSA on PSA” campaign for three years running rather than launching an entirely new initiative every Prostate Cancer Awareness Month, Rochelle cited both ...

For the first time, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown that it can extend ...

Weeks after telegraphing a series of upgrades to its Mexico operations over the next five years, Bayer is rolling up its ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped ...

In May, radiopharmaceutical drug developer Ratio Therapeutics unveiled plans to build a new research and manufacturing plant ...

As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. | BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer ...